Acromegaly After Surgery: Which Medical Therapy Fits a Borderline Glucose Tolerance
A single patient, six months past debulking surgery for a GH-secreting macroadenoma, with IGF-1 still elevated and a fasting glucose that is quietly drifting the wrong way. The disagreement is which of three real medical options actually fits a body that surgery has only partly fixed.
D.M., a 52-year-old man, has spent the better part of thirty years running a small engine-repair shop out of his garage, work that depends on hands steady enough to set a carburetor jet and a grip strong enough to break a rusted bolt free — both of which, he says, have quietly gotten easier over the past year, not harder, which is the detail that finally sent him to a doctor rather than the ring size he'd already stopped mentioning to his wife. His acromegaly was diagnosed eight months ago after an optometrist, working through why his vision kept changing prescription, noticed the coarsened facial features and ordered a growth hormone panel almost as an afterthought. A 2.6cm GH-secreting macroadenoma with cavernous sinus contact but no frank invasion was resected six months ago; surgical pathology confirmed a densely granulated somatotroph adenoma, and his visual fields, compressed preoperatively, have fully recovered. What surgery has not fixed is the biochemistry: his IGF-1 today is 1.6 times the upper limit of normal for his age, down from 3.4 times preoperatively but still clearly abnormal, and an oral glucose tolerance test drawn as part of routine post-op reassessment failed to suppress his GH below 1 ng/mL, confirming persistent disease rather than a slow biochemical remission still catching up to the anatomy.
The complicating detail is his fasting glucose, 112 mg/dL on this visit and 106 mg/dL six weeks ago — not yet diabetes, but a real trajectory, and one that predates any of the three drugs now under discussion, since acromegaly's own chronic GH excess is independently diabetogenic through hepatic insulin resistance. That baseline drift matters directly to which medical therapy comes next. First-generation somatostatin analogs (octreotide, lanreotide) are guideline first-line therapy for persistent disease and are glucose-neutral to mildly favorable, since suppressing GH itself tends to improve the insulin resistance GH excess was causing. Pasireotide, a second-generation analog with broader receptor affinity, achieves biochemical control in patients who fail first-generation agents specifically because it binds SSTR5 as well as SSTR2 — but does so partly by suppressing insulin and incretin secretion directly, a mechanism unrelated to its GH-lowering effect and one that has produced hyperglycemia in a clear majority of trial patients, including many with no diabetes risk at baseline. D.M. already has one.
Six months after surgery, the biochemistry hasn't caught up
Start with an increased dose of his current lanreotide rather than switching drug class. He's six months out, on a starting dose, and has already dropped his IGF-1 by more than half without any medical therapy in the interval — that's surgical debulking still working its way through, and first-generation somatostatin analogs are the guideline first-line agent for exactly this situation, per the Endocrine Society's own acromegaly guideline.
His glucose trend is real but it's 106 to 112, not yet diabetes, and lanreotide is glucose-neutral to mildly favorable in most patients because it's suppressing the actual diabetogenic driver — his GH excess — rather than adding a second mechanism on top of it.
I'd want a harder look at pasireotide before settling on dose escalation. He's failed adequate biochemical control on a first-generation agent's usual ceiling before — this isn't a treatment-naive patient, he was already on lanreotide going into today's labs — and pasireotide's PAOLA trial specifically enrolled patients inadequately controlled on octreotide or lanreotide, exactly his situation, and got roughly a fifth of them to normalize IGF-1 where continued first-generation therapy got almost none.
The glucose data from that same trial is the part I don't think we can wave off as a someday problem. A clear majority of PAOLA's patients developed hyperglycemia, many needing new antidiabetic therapy, and he's not walking in with a clean metabolic slate — he's walking in with two consecutive fasting glucoses trending toward the diagnostic threshold before we've added anything.
Both of you are arguing about the drug that lowers GH. There's a real argument for the drug that never touches insulin secretion at all: pegvisomant. It's a GH-receptor antagonist, not a somatostatin analog, so it doesn't share pasireotide's mechanism for causing hyperglycemia — if anything, blocking GH's own anti-insulin effect at the receptor tends to improve insulin sensitivity, which is the opposite direction of where his glucose is heading.
The honest tradeoff, and the reason I'm not calling this settled: pegvisomant normalizes IGF-1 in the large majority of patients who reach adequate dosing, but GH and IGF-1 stop being usable markers of tumor activity once you're blocking the receptor rather than the secretion — his residual cavernous-sinus tissue would need to be followed by MRI alone going forward, on a schedule we'd need to commit to explicitly, not just by drawing the labs everyone's used to reading.
Agreed: continue lanreotide at its current dose rather than escalate it, and add pegvisomant now, given the glucose trend already in motion before any new drug is started. Repeat IGF-1 at 8 weeks to gauge the combination's effect, with pituitary MRI moved to every 6 months rather than annually while pegvisomant is in the regimen, since GH and IGF-1 will no longer reliably flag tumor activity on their own.
Not agreed: whether pasireotide should be considered a later option if the combination fails, or whether its glucose-safety profile in a patient who is now trending toward diabetes on two other counts rules it out for him specifically going forward. The endocrine surgeon's read is that pasireotide's larger biochemical-control edge is worth revisiting even then; the clinical pharmacologist would rather escalate pegvisomant's dose first and treat pasireotide as a last resort, not a next step.